CD30 in Systemic Mastocytosis

被引：19
作者：
van Anrooij, Bjorn [1 ]
Kluin, Philip M. [2 ]
Elberink, Joanne N. G. Oude [1 ]
Kluin-Nelemans, Johanna C. [3 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, Dept Allergol, NL-9713 GZ Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, NL-9713 GZ Groningen, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, NL-9713 GZ Groningen, Netherlands
来源：
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA | 2014年 / 34卷 / 02期
关键词：
CD30; Soluble CD30; ligand; CD153; Systemic mastocytosis; LARGE-CELL LYMPHOMA; HODGKINS-DISEASE; SOLUBLE CD30; T-CELLS; B-CELLS; BRENTUXIMAB VEDOTIN; MYCOSIS-FUNGOIDES; LIGAND EXPRESSION; HUMAN EOSINOPHILS; SERUM-LEVEL;
D O I：
10.1016/j.iac.2014.01.006
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
CD30 is a transmembrane receptor, normally not expressed by mast cells, which regulates proliferation/apoptosis and antibody responses. Aberrant expression of CD30 by mastocytosis mast cells and interaction with its ligand CD30L (CD153) appears to play an important role in the pathogenesis and clinical presentation of systemic mastocytosis. This article highlights the expression profile and role of CD30 and CD3OL in physiologic and pathologic conditions, the applicability of CD30 as a marker for systemic mastocytosis, the consequences of mast cell-expressed CD30, and the possibility of future anti-CD30 based cytoreductive therapies.
引用
收藏
页码：341 / +
页数：16
相关论文
共 95 条
  • [91] Wiley SR, 1996, J IMMUNOL, V157, P3635
  • [92] OX40 and CD30 signals in CD4+ T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4+ T-cell memory but not effector function
    Withers, David R.
    Gaspal, Fabrina M.
    Bekiaris, Vasileios
    McConnell, Fiona M.
    Kim, MiYeon
    Anderson, Graham
    Lane, Peter J. L.
    [J]. IMMUNOLOGICAL REVIEWS, 2011, 244 : 134 - 148
  • [93] Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
    Younes, Anas
    Bartlett, Nancy L.
    Leonard, John P.
    Kennedy, Dana A.
    Lynch, Carmel M.
    Sievers, Eric L.
    Forero-Torres, Andres
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19) : 1812 - 1821
  • [94] MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival
    Zheng, B
    Fiumara, P
    Li, YV
    Georgakis, G
    Snell, V
    Younes, M
    Vauthey, JN
    Carbone, A
    Younes, A
    [J]. BLOOD, 2003, 102 (03) : 1019 - 1027
  • [95] CD30 Expression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes
    Zheng, Wenli
    Medeiros, L. Jeffrey
    Hu, Ying
    Powers, Linda
    Cortes, Jorge E.
    Ravandi-Kashani, Farhad
    Kantarjian, Hagop H.
    Wang, Sa A.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (03) : 307 - 314
12345678910